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Abstract
Background: Previous surveys of organizations that support the development of evidence-informed health policies have
focused on organizations that produce clinical practice guidelines (CPGs) or undertake health technology assessments (HTAs).
Only rarely have surveys focused at least in part on units that directly support the use of research evidence in developing health
policy on an international, national, and state or provincial level (i.e., government support units, or GSUs) that are in some way
successful or innovative or that support the use of research evidence in low- and middle-income countries (LMICs).
Methods: We drew on many people and organizations around the world, including our project reference group, to generate
a list of organizations to survey. We modified a questionnaire that had been developed originally by the Appraisal of Guidelines,
Research and Evaluation in Europe (AGREE) collaboration and adapted one version of the questionnaire for organizations
producing CPGs and HTAs, and another for GSUs. We sent the questionnaire by email to 176 organizations and followed up
periodically with non-responders by email and telephone.
Results: We received completed questionnaires from 152 (86%) organizations. More than one-half of the organizations (and
particularly HTA agencies) reported that examples from other countries were helpful in establishing their organization. A higher
proportion of GSUs than CPG- or HTA-producing organizations involved target users in the selection of topics or the services
undertaken. Most organizations have few (five or fewer) full-time equivalent (FTE) staff. More than four-fifths of organizations
reported providing panels with or using systematic reviews. GSUs tended to use a wide variety of explicit valuation processes
for the research evidence, but none with the frequency that organizations producing CPGs, HTAs, or both prioritized evidence
by its quality. Between one-half and two-thirds of organizations do not collect data systematically about uptake, and roughly the
same proportions do not systematically evaluate their usefulness or impact in other ways.
Conclusion: The findings from our survey, the most broadly based of its kind, both extend or clarify the applicability of the
messages arising from previous surveys and related documentary analyses, such as how the 'principles of evidence-based
medicine dominate current guideline programs' and the importance of collaborating with other organizations. The survey also
provides a description of the history, structure, processes, outputs, and perceived strengths and weaknesses of existing
organizations from which those establishing or leading similar organizations can draw.
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Background
Organizations that support the use of research evidence in
developing health policy can do so in many ways. Some
produce clinical practice guidelines (CPGs) or more gen-
erally guidance for clinicians and public health practition-
ers. Others undertake health technology assessments
(HTAs) with a focus on informing managerial and policy
decisions about purchasing, coverage, or reimbursement.
Still others directly support the use of research evidence in
developing health policy on an international, national,
and state or provincial level (hereafter called government
support units, or GSUs). As we argued in the introductory
article in the series, a review of the experiences of such
organizations, especially those based in low- and middle-
income countries (LMICs) and that are in some way suc-
cessful or innovative, can reduce the need to 'reinvent the
wheel' and inform decisions about how best to organize
support for evidence-informed health policy develop-
ment processes, particularly in LMICs [1].
We focus here on describing the methods and findings
from the first phase of a three-phase, multi-method study
(Table 1) [2]. In this phase we surveyed a senior staff
member (the director or his or her nominee) of CPG-pro-
ducing organizations, HTA agencies, and GSUs about
their history, structure, processes, outputs, and perceived
strengths and weaknesses. Previous surveys of organiza-
tions that support the development of evidence-informed
health policies have focused on organizations that pro-
duce CPGs [3-10], or undertake HTAs [11-14]. Only rarely
have surveys focused at least in part on GSUs [15], or on
organizations that are in some way successful or innova-
tive [9], and to our knowledge surveys have never focused
at least in part on organizations that support the use of
research evidence in LMICs. In the following two articles
in the series, we provide more detail about the methods
and findings from the interview and case descriptions
phases of the study [16,17].
Methods
We drew on many people and organizations around the
world, including our project reference group, to generate
a list of organizations to survey [2]. We modified a ques-
tionnaire that had been developed originally by the
Appraisal of Guidelines for Research and Evaluation
(AGREE) collaboration, adapted one version of the ques-
tionnaire for organizations producing CPGs and HTAs
and another for GSUs, piloted both versions of the ques-
tionnaire, and made a small number of final modifica-
tions to both versions of the questionnaire. We sent the
questionnaire by email to 176 organizations and followed
up periodically with non-responders by email and tele-
phone.
Study population
Eligible CPG-producing organizations, HTA agencies, and
GSUs had to perform at least one of the following functions
(or a closely related function): 1) produce systematic
reviews, HTAs, or other types of syntheses of research evi-
dence in response to requests from decision-makers (i.e., cli-
nicians, health system managers, and public policymakers);
2) identify and contextualise research evidence in response
to requests from decision-makers; and/or 3) plan, commis-
sion, or carry out evaluations of health policies in response
to requests from decision-makers. The GSUs could include
units located within a health system, government or interna-
tional organization, units hosted within a university or other
research-intensive organization, and independent units with
a mandate to directly support evidence-informed health pol-
icy (including health care policy, public health policy, and
healthy public policy). We excluded organizations that
receive core funding from industry (e.g., pharmaceutical
companies) or that only produce or provide health or
healthcare utilization data.
While we included all eligible organizations from LMICs, for
high-income countries we included: 1) established CPG-pro-
ducing organizations that are members of the Guidelines
International Network (GIN) and select other organizations
that are known to produce CPGs in particularly innovative or
successful ways; 2) established HTA agencies that are mem-
bers of the International Network of Agencies for Health
Technology Assessment (INAHTA) and select other HTA
agencies that are known to produce HTAs in particularly
Table 1: Overview of the four-article series
[1] Synthesis of findings from the three-phase, multi-method study
This article Survey of a senior staff member (the director or his or her nominee) of clinical practice guideline-
producing organizations, HTA agencies, and government support units
[16] Interview with the senior staff member of a purposively sampled sub-group of these three types of organizations, with an 
emphasis on those organizations that were particularly successful or innovative
[17] Case descriptions (based on site visits) of one or more organizations supporting the use of research evidence from 
among the cases described in the interviews and (once) other cases with which we were familiar, again with an emphasis 
on those organizations that were particularly successful or innovativeImplementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
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innovative or successful ways; and 3) any units that directly
support the use of research evidence in developing health
policy. We drew on members of both formal and informal
international networks to identify particularly innovative or
successful CPG-producing organizations and HTA agencies
and to identify GSUs. The formal networks included the
Appraisal of Guidelines for Research and Evaluation
(AGREE) collaboration, the Cochrane Collaboration, GIN,
GRADE Working Group, International Clinical Epidemiol-
ogy Network (INCLEN) Knowledge Management Program,
and INAHTA. The informal networks included our project
reference group, staff at WHO headquarters and regional
offices, and personal networks.
Survey development and administration
We drew on a questionnaire developed and used by the
AGREE collaboration [9], and we modified questions as
necessary given our focus on LMICs. The questions cov-
ered seven domains: 1) organization; 2) why and how the
organization was established; 3) focus; 4) people
involved; 5) methodology employed; 6) products and
implementation; and 7) evaluation and update proce-
dures. We also included a final group of additional ques-
tions. About two-fifths of the questions were open-ended.
Two of the questions were changed for the version of the
questionnaire administered to GSUs; this questionnaire
had 48 questions instead of 49. We piloted the question-
naire with three organizations in each category (and
received responses from five organizations). See 'Addi-
tional file 1: Questionnaire – CPG & HTA' for the ques-
tionnaire for units producing CPGs or HTAs, and see
'Additional file 2: Questionnaire – GSU' for the question-
naire for units supporting health policy.
We sent the questionnaire by email to the director (or
another appropriate person) of each eligible organization
with three options for responding: by answering ques-
tions in the body of our email message and returning it;
by answering questions in a Word version of our ques-
tionnaire attached to our e-mail message and returning it;
or by printing a PDF version of our questionnaire, com-
pleting it by hand, and mailing it. We sent three reminders
if we did not receive a response (at roughly 2, 8 and 10
weeks after the original contact for most organization and
at roughly 1, 2.5 and 4 weeks for the organizations for
which we had difficulty tracking down contact informa-
tion), each time offering to re-send the questionnaire
upon request. We used additional mechanisms to increase
the response rate, including an endorsement letter and
personal contacts [18].
Data management and analysis
Quantitative data were entered manually and summa-
rized using simple descriptive statistics. Written com-
ments were grouped by question, and one member of the
team (RM) identified themes using a constant compara-
tive method of analysis. The findings were then independ-
ently reviewed by two members of the research team (AO
and JL).
The principal investigator for the overall project (AO),
who is based in Norway, confirmed that, in accordance
with the country's act on ethics and integrity in research,
this study did not require ethics approval from one of the
country's four regional committees for medical and health
research ethics. In keeping with usual conventions in sur-
vey research, we took the voluntary completion and
return of the survey as indicating consent. We did not
mention either treating participants' responses as confi-
dential data or safe-guarding participants' anonymity in
our initial request to participate in the study or in the
questionnaire itself. Nevertheless, we present only aggre-
gated data and take care to ensure that no individuals or
organizations can be identified. We shared a report on our
findings with participants and none of them requested
any changes to how we present the data.
Results
We sent 176 questionnaires, and 152 (86%) completed
questionnaires were returned. Ninety-five organizations
produce CPGs, HTAs, or both and 57 units support gov-
ernment policymaking (i.e., are what we call GSUs) (Table
2). Twenty-nine organizations were identified through the
GIN membership list, 26 through INAHTA, and 82
through personal contacts, including 49 of the 57 GSUs.
Although we intentionally sought out organizations in
LMIC, 56% (n = 85) were from high-income countries,
13% (n = 19) from upper middle-income countries, 24%
(n = 36) from lower middle-income countries and 5% (n
= 8) from low-income countries. Over one-half the organ-
izations (54%) that produced CPGs and HTAs were iden-
tified through GIN and INAHTA (51/95), and 68% (n =
65) were from high-income countries compared to 35%
(20/57) of GSUs. Although we aimed to identify organi-
zations throughout the world, the included organizations
were not spread evenly across different regions. Sixty-
seven percent (64/95) of the organizations that produce
CPGs and HTAs were located in Western Europe (n = 40),
North America (n = 17), Australia and New Zealand (n =
7), compared with 33% of GSUs (19/57). We identified
few organizations in Eastern Europe (n = 1), India (n = 2),
the Middle East (n = 3) or China (n = 4) that met our
inclusion criteria, and only three international organiza-
tions were included.
Quantitative results
Organization and establishment
A high proportion of organizations that produce CPGs,
HTAs, or both also support government policymaking in
other ways, whereas the reverse (GSUs producing CPGs or
HTAs) was much less common (Table 3). Among the arrayImplementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
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of services undertaken in response to requests from public
policymakers, GSUs are most likely to convene expert
meetings to discuss available research (82%) and under-
take short-term research projects (79%). Organizations
that produce CPGs were often based in professional asso-
ciations (45%) whereas organizations that produce HTAs,
or both CPGs and HTAs, were often based in government
agencies (63% and 49%, respectively). GSUs were also
often based in academic institutions (37%) and govern-
ment agencies (39%). HTA agencies were particularly
likely to receive funding from government sources (95%),
whereas the other types of organizations did not have
Table 2: Description of the units
Characteristics Organizations 
producing CPGs 
(n = 31)
Organizations 
producing HTAs 
(n = 19)
Organizations producing 
CPGs and HTAs (n = 45)
Organizations supporting 
government policymaking 
(n = 57)
All (n = 152)
Source from which units identified
GIN 13 0 13 3 29
INAHTA 1 17 7 1 26
INCLEN 5 0 5 4 14
Personal contacts 11 2 20 49 82
Other 1 0 0 0 1
Economic classification of the countries in which they units are based
Low-income 0 0 2 6 8
Lower-middle 
income
81 9 1 8 3 6
Upper-middle 
income
30 5 1 1 1 9
High income 20 18 27 20 85
Region in which they units are based
Africa 1 0 1 5 7
Asia 4 1 9 18 32
Australia and New 
Zealand
12 4 2 9
Eastern Europe 0 0 1 0 1
Western Europe 13 12 15 9 49
Latin America and 
the Caribbean
60 6 9 2 1
Middle East 0 1 0 3 4
North America 6 3 8 8 25
International 0 0 1 2 3Implementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
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Table 3: Organization and establishment
Characteristics Organizations producing 
CPGs (n = 31)
Organizations producing 
HTAs (n = 19)
Organizations producing 
CPGs and HTAs (n = 45)
Organizations supporting 
government policymaking 
(n = 57)
Type of product produced
Reported also providing 
direct support to 
policymakers for 
developing health policy
17 (55%) 16 (85%) 35 (78%) -
Reported also producing 
clinical practice guidelines
--- 1 7  ( 3 0 % )
Reported also producing 
HTAs
--- 1 1  ( 1 9 % )
Types of services undertaken in response to requests from public policymakers*
Identify primary research - - - 36 (63%)
Identify systematic reviews 
of research
--- 3 1  ( 5 4 % )
Identify clinical practice 
guidelines, HTAs or other 
prescriptive research-
based documents
--- 2 4  ( 4 2 % )
Undertake short-term 
research projects
--- 4 5  ( 7 9 % )
Undertake systematic 
reviews of research
--- 3 8  ( 6 7 % )
Commission systematic 
reviews of research
--- 1 7  ( 3 0 % )
Either undertake 
systematic reviews of 
research or commission 
systematic reviews of 
research
--- 4 1  ( 7 2 % )
Convene expert meetings 
to discuss available 
research
--- 4 7  ( 8 2 % )
O t h e r --- 1 8  ( 3 2 % )
Type of organization
Academic institution 7 (23%) 7 (37%) 11 (24%) 21 (37%)
Disease-specific association 1 (3%) 0 (0%) 1 (2%) 0 (0%)
Professional association 14 (45%) 2 (11%) 4 (9%) 3 (5%)
Government agency 9 (29%) 12 (63%) 22 (49%) 22 (39%)
International agency 0 (0%) 0 (0%) 3 (7%) 7 (12%)
Other 8 (26%) 2 (11%) 7 (16%) 18 (32%)
Source of funding*
Biomedical or other for-
profit company
7 (23%) 1 (5%) 6 (13%) 6 (11%)
Government 17 (55%) 18 (95%) 38 (84%) 45 (79%)
Other 15 (48%) 3 (16%) 20 (44%) 38 (67%)
Examples from other countries helpful in establishing the organization
Yes 18 (58%) 14 (74%) 24 (53%) 30 (53%)
No 8 (26%) 0 (0%) 15 (33%) 17 (30%)
Not reported 4 (13%) 4 (21%) 6 (13%) 7 (12%)
*More than one answer was possible for the questionImplementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
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such a commonly shared revenue source. More than one-
half of the organizations (and particularly HTA agencies)
reported that examples from other countries were helpful
in establishing their organization.
Age, budget and production profile
The organizations' ages, budgets, and production profiles
varied dramatically (Table 4). The median age was 7 to 10
years depending on the type of organization; however,
one organization had just begun directly supporting the
use of research evidence in developing health policy and
another had a 94-year history. The median annual budget
was lowest for CPG-producing organizations and highest
for HTA-producing organizations. The median number of
CPGs or HTAs produced per year ranged from three to
seven, and the median time spent to produce a CPG or
HTA ranged from 10 to 15 months.
Focus
Organizations producing CPGs were more often focused
on health care (65–84%) than on public health (45%) or
healthy public policy (26%), whereas GSUs were more
focused on public health (88%) and to a lesser extent on
primary healthcare (72%) and healthy public policy
(67%) (Table 5). A high proportion of GSUs provided
service on many facets of policy issues: characterizing
problems (74%), identifying potential solutions (82%),
fitting solutions into health systems (75%), and bringing
about change in health systems (88%). Organizations
producing CPGs were more focused on physicians
(100%) and to a lesser extent other types of healthcare
providers (77%) as their target users, whereas HTA agen-
cies were more focused on health system managers (95%)
and public policymakers (100%). GSUs were most
focused on public policymakers in health departments,
followed by public policymakers in central agencies
(77%), stakeholders (79%), and public policymakers in
other departments (63%). A higher proportion of GSUs
involved target users in the selection of topics or the serv-
ices undertaken than CPG- or HTA-producing organiza-
tions.
People involved in producing a product or delivering a service
Most organizations have a small number of full-time
equivalent (FTE) staff (Table 6). For example, more than
one-half of organizations producing CPGs, HTAs, or both
have between one and five FTE staff. More than one-half
of all organizations always involved an expert in informa-
tion/library science, and more than two-thirds of CPG-
and HTA-producing organizations always involved an
expert in clinical epidemiology. More than one-half of all
HTA agencies also always involved a health economist
and (only if necessary) involved experts in biostatistics,
other types of social scientists, and a consumer represent-
ative. More than two-thirds of organizations producing
CPGs or both CPGs and HTAs involve target users by
inviting them to participate in the development group or
to review the draft product. A higher proportion of GSUs
than other types of organizations involve consumers in
product development or service delivery. For example,
44% of GSUs invite consumers to participate in the devel-
opment group and 54% survey their views/preferences.
More than two thirds of organizations producing CPGs
consider geographic balance in expert or target user selec-
tion, but a lower proportion of other types of organiza-
tions use this criterion.
Table 4: Age, budget and production profile
Characteristics Organizations producing
CPGs
(n = 31)
Organizations producing
HTAs
(n = 19)
Organizations producing
CPGs and HTAs
(n = 45)
Organizations supporting 
government policymaking
(n = 57)
n Median Range n Median Range n Median Range n Median Range
Median years since 
began production/
service
28 9 2 to 27 18 8 3 to 20 44 7 1 to 27 55 10 0 to 94
Median annual 
budget 
(in US dollars)
26 368,275 500 to 
15,000,000
16 875,000 125,000 to 
21,600,000
38 700,000 5,000 to 
40,000,000
41 692,000 1,200 to 
51,000,000
Median number of 
CPGs or HTAs 
produced per year
31 3 0.5 to 500 17 7 2 to 45 42 7 1 to 300 - - -
Median time for 
production of a 
CPG or HTA 
(in months)
31 15 0.3 to 33 17 12 4 to 36 41 10 0.3 to 30 - - -Implementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
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Table 5: Focus
Characteristics Organizations producing 
CPGs
(n = 31)
Organizations producing 
HTAs
(n = 19)
Organizations producing 
CPGs and HTAs
(n = 45)
Organizations supporting 
government policymaking
(n = 57)
Domains from which topics are selected*
Primary healthcare 26 (84%) 18 (95%) 38 (84%) 41 (72%)
Secondary healthcare 25 (81%) 18 (95%) 33 (73%) 29 (51%)
Tertiary healthcare 20 (65%) 18 (95%) 32 (71%) 26 (46%)
Public health (i.e., health is 
the objective)
14 (45%) 15 (79%) 33 (73%) 50 (88%)
Health public policy 8 (26%) 9 (47%) 21 (47%) 38 (67%)
Domains in which service is provided*
Characterizing the problem - - - 42 (74%)
Identifying potential 
solutions to health 
problems
--- 4 7  ( 8 2 % )
Fitting solutions into health 
systems (i.e., governance, 
financial and delivery 
arrangements)
--- 4 3  ( 7 5 % )
Bringing about change in 
health systems
--- 5 0  ( 8 8 % )
Target users*
Patients/public 18 (58%) 13 (68%) 32 (71%) -
Physicians 31 (100%) 17 (89%) 43 (96%) -
Other types of healthcare 
providers
24 (77%) 15 (79%) 35 (78%) -
Healthcare managers 18 (58%) 18 (95%) 36 (80%) -
Public policymakers 18 (58%) 19 (100%) 37 (82%) -
Public policymakers in 
health departments
--- 5 0  ( 8 8 % )
Public policymakers in 
other departments
--- 3 6  ( 6 3 % )
Public policymakers in 
central agencies (e.g., 
executive branch)
--- 4 4  ( 7 7 % )
Stakeholders - - - 45 (79%)
Involvement of target users in selection of topics or services undertakenImplementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
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Methods used in producing a product or delivering a service
Organizations draw on a wide variety of types of informa-
tion (Table 7). More than four-fifths (84 to 100%) of
organizations reported providing panels with or using sys-
tematic reviews. Organizations producing CPGs, HTAs, or
both tended to use an explicit valuation process for the
research evidence (89 to 97% prioritized evidence by its
quality), but used one less often for outcomes (52 to 61%
prioritized outcomes by their importance to those
affected), and still less often for groups (0 to 26% priori-
tized groups by their importance to achieving equity
objectives). GSUs tended to use a wide variety of explicit
valuation processes, but none with the frequency that
organizations producing CPGs, HTAs, or both prioritized
evidence by its quality. A higher proportion of organiza-
tions producing CPGs, HTAs, or both graded recommen-
dations according to the quality of the evidence and/or
the strength of the recommendation than used other
methods to formulate recommendations. Roughly one-
half of GSUs used each of subjective review, consensus,
and grading to formulate recommendations. A higher
proportion of organizations producing CPGs, HTAs, or
both explicitly assessed the quality of evidence in formu-
lating recommendations than explicitly assessed the
trade-offs between benefits and harms, costs or equity.
Almost one-half of GSUs explicitly assessed equity in for-
mulating recommendations. A higher proportion of
organizations used internal review or external review by
experts than other review processes.
Products and implementation
All or almost all organizations producing CPGs, HTAs, or
both produced a full version of their final product with
references, whereas only HTA agencies uniformly pro-
duced both the full version and an executive summary
(Table 8). Less than one-half of all organizations provided
a summary of take-home messages as part of their prod-
ucts. More than two-thirds of organizations producing
CPGs, HTAs, or both posted to a website accessed by tar-
get users, and more than two thirds of organizations pro-
ducing HTAs or both CPGs and HTAs mailed or e-mailed
products to target users. Only 14% of GSUs submitted
products to any form of clearinghouse. More than one-
half of organizations were involved in different strategies
to develop the capacity of target users to acquire, assess,
and use their products or services. Almost two-thirds of
GSUs involved target users in an implementation group,
whereas lower proportions of other types of organizations
involved target users in implementation through this or
another approach.
Evaluation and update procedures
Between one-half and two-thirds of organizations do not
collect data systematically about uptake, and roughly the
same proportions do not systematically evaluate their use-
fulness or impact in other ways (Table 9). A little over one-
half (52%) of organizations producing CPGs update their
products regularly whereas less than one-half (45%)
update them irregularly. A higher proportion of other
types of organizations update their products and services
irregularly (49 to 63%) than regularly (11 to 37%).
Qualitative results
See additional file 3: Qualitative data for the qualitative
data from the survey of organizations that support the use
of research evidence
Discussion
Principal findings from the survey
A high proportion of organizations that produce CPGs,
HTAs, or both also support government policymaking in
other ways, whereas the reverse (GSUs producing CPGs or
HTAs) was much less common. More than one-half of the
organizations (and particularly HTA agencies) reported
that examples from other countries were helpful in estab-
lishing their organization. The organizations' ages, budg-
By participation in priority-
setting group or working 
groups
18 (58%) 13 (68%) 28 (62%) 50 (88%)
By survey of views/
preferences
14 (45%) 6 (32%) 20 (44%) 35 (61%)
By review of draft list of 
priority topics or draft 
reports
15 (48%) 5 (26%) 21 (27%) 43 (75%)
No 6 (19%) 2 (11%) 7 (16%) 0 (0%)
Not reported 1 (3%) 1 (5%) 1 (2%) 3 (5%)
*More than one answer was possible for the question
Table 5: Focus (Continued)Implementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
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Table 6: People involved in producing a product or delivering a service
Characteristics Organizations producing 
CPGs
(n = 31)
Organizations producing 
HTAs
(n = 19)
Organizations producing 
CPGs and HTAs
(n = 45)
Organizations supporting 
government policymaking 
(n = 57)
Average number of members in a CPG or HTA development panel
1–5 full time equivalents 
(FTE)
17 (55%) 11 (58%) 23 (51%) -
6–10 FTE 9 (29%) 5 (26%) 11 (24%) -
11–15 FTE 2 (6%) 0 (0%) 5 (11%) -
16–20 FTE 1 (3%) 1 (5%) 1 (2%) -
> 20 FTE 2 (6%) 1 (5%) 3(7%) -
Not reported 1 (3%) 1 (5%) 1 (2%) -
Average number of staff involved in service delivery
< 0.5 full time equivalents 
(FTE)
- - - 8 (14%)
0.5 – 1.9 FTE - - - 6 (11%)
> 2 FTE - - - 37 (65%)
Types of experts/stakeholders who were always involved*
Information/library science 19 (61%) 16 (84%) 27 (60%) 29 (51%)
Clinical epidemiology 21 (68%) 14 (74%) 32 (71%) 24 (42%)
Biostatistics 3 (10%) 6 (32%) 17 (38%) 23 (40%)
Health economics 5 (16%) 10 (53%) 17 (38%) 24 (42%)
Other types of social 
scientists
4 (13%) 4 (21%) 12 (27%) 23 (40%)
Knowledge transfer/
communications
10 (32%) 8 (42%) 21 (47%) 24 (42%)
Consumer 9 (29%) 3 (16%) 17 (38%) 15 (26%)
Other 7 (23%) 9 (47%) 13 (29%) 15 (26%)
Types of experts/stakeholders who were involved only if necessary*
Information/library science 10 (32%) 2 (11%) 13 (29%) 22 (39%)
Clinical epidemiology 8 (26%) 4 (21%) 11 (24%) 22 (39%)
Biostatistics 16 (52%) 12 (63%) 19 (42%) 26 (46%)
Health economics 15 (48%) 9 (47%) 23 (51%) 26 (46%)Implementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
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ets and production profiles varied dramatically. A higher
proportion of GSUs than CPG- or HTA-producing organ-
izations involved target users in the selection of topics or
the services undertaken. Most organizations have a small
number of FTE staff (e.g., five or fewer FTEs for CPG- and
HTA-producing organizations). More than one-half of all
organizations always involved an expert in information/
library science, and more than two-thirds of CPG- and
HTA-producing organizations always involved an expert
in clinical epidemiology. More than four-fifths of organi-
zations reported providing panels with or using system-
atic reviews. GSUs tended to use a wide variety of explicit
valuation processes for the research evidence, but none
with the frequency that organizations producing CPGs,
HTAs, or both prioritized evidence by its quality. Less than
one-half of all organizations provided a summary of take-
Other types of social 
scientists
14 (45%) 15 (79%) 26 (58%) 24 (42%)
Knowledge transfer/
communications
8 (26%) 8 (42%) 9 (20%) 23 (40%)
Consumer 12 (39%) 11 (58%) 11 (24%) 24 (42%)
Other 2 (6%) 4 (21%) 3 (7%) 5 (9%)
Involvement of target users in product development or service delivery
By participation in 
development/delivery 
group
25 (81%) 11 (58%) 33 (73%) -
By survey of views/
preferences
9 (29%) 2 (11%) 18 (40%) -
By review of draft product 
or service model
22 (71%) 9 (47%) 32 (71%) -
No 0 (0%) 3 (16%) 3 (7%)
Not reported 0 (0%) 2 (11%) 1 (2%) -
Involvement of consumers (patients or general public) in product development or service delivery
By participation in 
development group
12 (39%) 3 (16%) 16 (36%) 25 (44%)
By survey of views/
preferences
9 (29%) 2 (11%) 14 (31%) 31 (54%)
By review of draft guideline 
(or HTA)
14 (45%) 5 (26%) 23 (51%) 17 (30%)
No 10 (32%) 9 (47%) 13 (29%) 15 (26%)
Not reported 1 (3%) 2 (11%) 1 (2%) 1 (2%)
Criteria used in expert and/or target user selection*
Geographic balance 21 (68%) 7 (37%) 18 (40%) -
Gender balance 8 (26%) 2 (11%) 8 (18%) -
Other 18 (58%) 11 (58%) 25 (56%) -
*More than one answer was possible for the question
Table 6: People involved in producing a product or delivering a service (Continued)Implementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
Page 11 of 17
(page number not for citation purposes)
Table 7: Methods used in producing a product or delivering a service
Characteristics Organizations producing 
CPGs
(n = 31)
Organizations producing 
HTAs
(n = 19)
Organizations producing 
CPGs and HTAs
(n = 45)
Organizations supporting 
government policymaking 
(n = 57)
Types of information provided to the panel or employed*
Systematic reviews 31 (100%) 16 (84%) 42 (93%) 49 (86%)
Economic evaluations 15 (48%) 15 (79%) 24 (53%) 34 (60%)
Decision analyses 13 (42%) 9 (47%) 23 (51%) 29 (51%)
Existing burden of disease/
illness
26 (84%) 17 (89%) 34 (76%) 38 (67%)
Existing practice patterns 21 (68%) 14 (74%) 33 (73%) 33 (58%)
Existing guidelines 
(or HTAs)
30 (97%) 15 (79%) 41 (91%) 38 (67%)
Resource constraints 11 (35%) 10 (53%) 18 (40%) 26 (46%)
Commissioned research - - - 27 (47%)
Other 7 (23%) 5 (26%) 9 (20%) 10 (18%)
Explicit valuation process used*
Evidence is prioritized by 
its quality
30 (97%) 17 (89%) 41 (91%) 40 (70%)
Outcomes are prioritized 
by their importance to 
those affected
19 (61%) 10 (53%) 28 (52%) 39 (68%)
Groups are prioritized by 
their importance to 
achieving equity objectives
8 (26%) 0 (0%) 11 (24%) 27 (47%)
Methods used to formulate recommendations*
Subjective review 5 (16%) 5 (26%) 12 (27%) 26 (46%)
Informal consensus 10 (32%) 9 (47%) 11 (24%) 28 (49%)
Formal consensus (e.g., 
nominal group or Delphi 
techniques)
18 (58%) 3 (16%) 19 (42%) 29 (51%)
Graded according to the 
quality of the evidence and/
or the strength of the 
recommendation 
(using an explicit rating 
scheme)
26 (84%) 12 (63%) 34 (76%) 31 (54%)
Explicit assessments used in formulating recommendations*
Quality of evidence 29 (94%) 16 (84%) 43 (96%) 41 (72%)Implementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
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home messages as part of their products. Almost two-
thirds of GSUs involved target users in an implementation
group, whereas lower proportions of other types of organ-
izations involved target users in implementation through
this or another approach. Between one-half and two-
thirds of organizations do not collect data systematically
about uptake, and roughly the same proportions do not
systematically evaluate their usefulness or impact in other
ways.
For CPG- and HTA-producing organizations, specifically:
1) when they were being established, many conducted a
focused review of one particular organization that they
then emulated or a broad review of a variety of organiza-
tional models; 2) independence is by far the most com-
monly cited strength in how they are organized and a lack
of resources, both financial and human, the most com-
monly cited weakness; 3) an evidence-based approach is
the most commonly cited strength of the methods they
use and their methods' time-consuming and labour-
intensive nature the most commonly cited weakness; 4)
the brand recognition that was perceived to flow from
their evidence-based approach, and much less commonly
from their strict conflict-of-interest guidelines, is the main
strength of their outputs, while the most commonly cited
weaknesses were the lack of dissemination and imple-
mentation strategies for the outputs and the lack of mon-
itoring and evaluation of impact; 5) the individuals,
groups, and organizations who have worked with them or
who have benefited from their outputs are their strongest
advocates, and the pharmaceutical industry and clinicians
who are closely associated with them their strongest crit-
ics; and 6) a facilitating role in coordination efforts (in
order to avoid duplication) and in local adaptation efforts
(in order to enhance local applicability) are their most fre-
quently offered suggestions for WHO and other interna-
tional agencies and networks.
For GSUs: 1) focusing on the need for secure funding
when establishing a GSU was their most commonly
offered advice; 2) working within national networks and,
more generally, collaborating rather than competing with
other bodies, was a commonly cited strength in how these
units are organized; 3) government health departments
are their strongest advocates; and 4) helping to adapt glo-
bal evidence to local contexts or at least supporting such
processes are their most frequently offered suggestions for
WHO and other international agencies and networks. No
themes emerged with any consistency among the diverse
weaknesses identified in how the units were organized,
strengths and weaknesses identified in their methods and
outputs, or critics cited.
Strengths and weaknesses of the survey
The survey has four main strengths: 1) we surveyed the
directors of three types of organizations that support evi-
dence-informed policymaking, not just the two types of
organizations that are usually studied (i.e., we surveyed
GSUs as well as CPG- and HTA-producing organizations);
2) we adapted a widely used questionnaire; 3) we drew on
a regionally diverse project reference group to ensure that
our draft protocol, study population, and questionnaire
Trade-offs between 
benefits and harms
20 (65%) 9 (47%) 35 (78%) 35 (61%)
Costs 14 (45%) 12 (63%) 30 (67%) 31 (54%)
Equity 9 (29%) 6 (32%) 21 (47%) 27 (47%)
Review processes used*
Clinical or policy validation 
(e.g., pilot testing, trial 
implementation period)
9 (29%) 3 (16%) 11 (24%) 24 (42%)
Comparison with products 
or input from other groups
15 (48%) 5 (26%) 27 (60%) 19 (33%)
Internal review 26 (84%) 17 (89%) 38 (84%) 41 (72%)
External review by experts 24 (77%) 16 (84%) 42 (93%) 43 (75%)
External review by target 
users
18 (58%) 5 (26%) 21 (47%) 23 (40%)
*More than one answer was possible for the question
Table 7: Methods used in producing a product or delivering a service (Continued)Implementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
Page 13 of 17
(page number not for citation purposes)
Table 8: Products and implementation
Characteristics Organizations producing 
CPGs
(n = 31)
Organizations producing 
HTAs
(n = 19)
Organizations producing 
CPGs and HTAs
(n = 45)
Organizations supporting 
government policymaking 
(n = 57)
Versions produced*
Full version with notes/
references
31 (100%) 19 (100%) 44 (98%) 46 (81%)
Executive summary 20 (65%) 19 (100%) 32 (71%) 40 (70%)
Summary of take-home 
messages
14 (45%) 5 (26%) 20 (44%) 25 (44%)
Separate summaries/
versions for different target 
users
10 (32%) 5 (26%) 21 (47%) 24 (42%)
Tools for application (e.g., 
algorithms, flow charts)
18 (58%) 2 (11%) 26 (58%) 28 (49%)
Produce at least one of the 
above 4 versions
27 (87%) 19 (100%) 37 (82%) 49 (86%)
Dissemination/implementation strategies used*
Send versions of products 
to the media
21 (68%) 10 (53%) 27 (60%) 32 (56%)
Mail or e-mail products to 
target users
19 (61%) 15 (79%) 33 (73%) 38 (67%)
Produce a CD-ROM and 
distribute it to target users
6 (19%) 2 (11%) 17 (38%) 20 (35%)
Post to a website accessed 
by target users
27 (87%) 13 (68%) 32 (71%) 42 (74%)
Submit to a clearinghouse 16 (52%) 11 (58%) 17 (38%) 8 (14%)
Other 20 (65%) 9 (47%) 18 (40%) 20 (35%)
Other implementation strategies used*
Patient-mediated 
interventions
7 (23%) 2 (11%) 11 (24%) 8 (14%)
Provider-mediated 
interventions
15 (48%) 6 (32%) 18 (40%) 23 (40%)
Organizational 
interventions
15 (48%) 10 (53%) 18 (40%) 27 (47%)
Strategies used to develop the capacity of target users to acquire, assess and use products they produce or services they deliver*
Organize training 
workshops for target users
19 (61%) 12 (63%) 31 (69%) 42 (74%)
Participate in training 
workshops for target users
17 (55%) 8 (42%) 31 (69%) 36 (63%)Implementation Science 2008, 3:54 http://www.implementationscience.com/content/3/1/54
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were fit for purpose; and 4) we achieved a high response
rate (86%). The study has two main weaknesses: 1)
despite significant efforts to identify organizations in
LMICs, just over one-half (54%) of the organizations we
surveyed were drawn from high-income countries; and 2)
despite efforts to ask questions in neutral ways, many
organizations may have been motivated by a desire to tell
us what they thought we wanted to hear (i.e., there may be
a social desirability bias in their responses).
What the survey adds
The findings from our survey, the most broadly based of
its kind, both extend or clarify the applicability (to HTA
agencies, GSUs or both) of the messages arising from pre-
vious surveys and related documentary analyses and add
several new messages. First, our findings concur with the
conclusion of the most recent and comprehensive survey
of CPG-producing organizations that 'principles of evi-
dence-based medicine dominate current guideline pro-
grams' [9], although this was less true of the broad variety
of GSUs that we surveyed. Our findings also concur with
their conclusion that 'international collaboration should
be encouraged to improve guideline methodology and to
globalize the collection and analysis of evidence needed
for guideline development', which appears equally ger-
mane to the HTA agencies and the GSUs we surveyed. Sec-
ond, our findings concur with the most recent survey of
HTA agencies, which focused on the risks to HTA pro-
grams (grouped into the categories of formulation of HTA
questions, preparation of HTA products, dissemination,
and contracting) and the management of those risks, spe-
cifically the conclusions related to establishing strong
links with policymakers and involving stakeholders in the
work, using good methods and being transparent in the
work, and being attentive to implementation considera-
tions [14]. Third, our findings concur with the conclu-
sions of several reviews of CPG and HTA documents,
particularly the importance of using good methods and
being transparent, collaborating with other organizations,
and building capacity [19-24]. Our survey also provides a
description of the history, structure, processes, outputs,
and perceived strengths and weaknesses of GSUs as well as
CPG- and HTA-producers, which can be a useful resource
for those establishing or leading similar organizations in
LMICs.
Implications for policymakers and for international 
organizations and networks
Both policymakers and international organizations and
networks can play an important facilitating role in coordi-
nation efforts (in order to avoid duplication) and in local
adaptation efforts (in order to enhance local applicabil-
ity). They also have an important advocacy role to play in
calling for coordination and local adaptation. Interna-
tional organizations and networks can play several addi-
tional facilitation roles, particularly in the areas of sharing
robust methodologies and where necessary improving
existing methodologies (which could include establishing
a common framework for evaluations of their impact in
order to facilitate cross-organization and cross-jurisdic-
Either organize or 
participate in training 
workshops for target users
25 (81%) 12 (63%) 34 (76%) 43 (75%)
Develop a resource 
document for target users
19 (61%) 10 (53%) 26 (58%) 38 (67%)
Other 5 (16%) 6 (32%) 5 (11%) 5 (9%)
Involvement of target users in implementation
By participation in 
implementation group
15 (48%) 8 (42%) 26 (58%) 37 (65%)
By survey of views/
preferences
9 (29%) 6 (32%) 18 (40%) 28 (49%)
By review of draft 
implementation strategy
10 (32%) 5 (26%) 14 (31%) 19 (33%)
No 8 (26%) 3 (16%) 5 (11%) 1 (2%)
Not reported 2 (6%) 3 (16%) 9 (20%) 9 (16%)
*More than one answer was possible for the question
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tion learning), collecting and analyzing 'global' research
evidence and making it available as an input to 'local'
processes, and engaging more organizations based in
LMICs and providing training and support for their con-
tinued development. Select international organizations,
such as the Alliance for Health Policy and Systems
Research, may have a particular role to play in sponsoring
the development of an international organization of
GSUs, which can be difficult to identify, let alone support.
Implications for future research
The survey should be repeated in a few years on an aug-
mented sample of organizations, including organizations
that have self-identified as partners of the Alliance for
Health Policy and Systems Research (many of which may
be GSUs). Also, as suggested above, there is a need for
improving some of the existing methodologies used by
the organizations and for establishing a common frame-
work for evaluations of their impact.
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